文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

肾静脉多普勒超声引导的中心静脉压滴定在脓毒症中的影响:一项先导性随机对照试验

Impact of renal vein doppler ultrasound-guided CVP titration in sepsis: a pilot randomized controlled trial.
PubMed 文献 · Crit Care · 2026-01-24
一句话结论在脓毒症患者中,肾静脉多普勒超声引导的中心静脉压滴定方案可行(100%完成),并与更多的降阶梯治疗和更低的液体平衡相关,但临床结局差异仅为探索性信号。

这项前瞻性、单中心、平行组先导性随机对照试验在ICU于2023年4月至12月纳入127例脓毒症并监测中心静脉压的成人患者,1:1随机分为肾静脉多普勒引导的中心静脉压滴定组(RVD-CVP,63例)和常规护理组(64例)。干预组在0、6、24、48、72小时进行肾静脉多普勒评估,并按预设中心静脉压目标维持、降低或推迟。主要终点方案完全实施在干预组达63/63(100.0%,95%CI 94.3–100.0),所有计划评估完成315/315(100.0%),安全 override 推迟17/315(5.4%)。7天内AKI进展为对照组37/64(57.0%)vs 干预组27/63(43.0%),RR 0.74(95%CI 0.52–1.06);干预组RRT启动率更低(9.52% vs 23.44%,RR 0.41,95%CI 0.17–0.98,P=0.035),RRT持续时间更短(0.84天 vs 2.39天,P=0.03)。28天死亡率为7.9% vs 12.5%,干预组28天无升压药天数更多(均值22.12 vs 18.84天),最大去甲肾上腺素剂量更低(均值0.423 vs 0.560 µg/kg/min)。作者结论认为该方案可行并与更多降阶梯和更低液体平衡相关,但AKI相关结局和RRT使用差异为预设探索性次要发现,试验把握度不足以对临床结局得出确定性结论,这些信号需在更大样本

要点

  • 在脓毒症并监测CVP的成人中,RVD-CVP方案完全实施率达63/63(100.0%,95%CI 94.3–100.0),所有计划肾静脉多普勒评估完成315/315(100.0%)。
  • 7天内AKI进展:对照组37/64(57.0%)vs 干预组27/63(43.0%),RR 0.74(95%CI 0.52–1.06),未达统计学显著。
  • RRT启动率干预组9.52% vs 对照组23.44%,RR 0.41(95%CI 0.17–0.98,P=0.035);RRT持续时间干预组0.84天 vs 对照组2.39天(P=0.03)。
  • 28天死亡率干预组7.9% vs 对照组12.5%;28天无升压药天数均值干预组22.12天 vs 对照组18.84天;最大去甲肾上腺素剂量均值干预组0.423 µg/kg/min vs 对照组0.560 µg/kg/min。
  • 作者指出AKI相关结局与RRT使用差异为预设探索性次要发现,试验把握度不足以对临床结局得出确定性结论,需在更大样本、足够把握度的随机对照试验中确认。

适用人群与场景

  • 成人脓毒症患者,在ICU接受中心静脉压监测,于2023年4月至12月在一家单中心ICU纳入。

处置流程与药物剂量

  • 干预组接受肾静脉多普勒引导的中心静脉压滴定方案(RVD-CVP):在0、6、24、48、72小时进行肾静脉多普勒评估,并按预设中心静脉压目标维持、降低或推迟。
  • 对照组接受不包含肾静脉多普勒引导的常规护理。

研究设计与关键结果

  • 研究类型:前瞻性、单中心、平行组先导性随机对照试验;筛查173例,随机127例(干预组63例,对照组64例)。
  • 主要终点可行性:干预组方案完全实施63/63(100.0%,95%CI 94.3–100.0),所有计划肾静脉多普勒评估完成315/315(100.0%),安全 override 推迟17/315(5.4%)。
  • 7天内AKI进展:对照组37/64(57.0%)vs 干预组27/63(43.0%),RR 0.74(95%CI 0.52–1.06)。
  • RRT启动率:干预组9.52% vs 对照组23.44%,RR 0.41(95%CI 0.17–0.98,P=0.035);RRT持续时间:干预组0.84天 vs 对照组2.39天(P=0.03)。
  • 28天死亡率:干预组7.9% vs 对照组12.5%。
  • 28天无升压药天数均值:干预组22.12天 vs 对照组18.84天;最大去甲肾上腺素剂量均值:干预组0.423 µg/kg/min vs 对照组0.560 µg/kg/min。

证据类型、等级与局限

  • 证据类型:先导性随机对照试验。
  • 作者指出AKI相关结局和RRT使用(包括CRRT)差异为预设探索性次要发现,试验把握度不足以对临床结局得出确定性结论。
  • 作者结论认为这些信号应谨慎解读,需在更大样本、足够把握度的随机对照试验中确认。

对床旁实践的改变

  • 作者认为肾静脉多普勒超声引导的中心静脉压滴定在脓毒症患者中可行,并与更多降阶梯治疗和更低液体平衡相关。
  • 作者指出AKI相关结局与RRT使用差异为探索性次要发现,试验把握度不足以对临床结局得出确定性结论,这些信号应谨慎解读并在更大样本、足够把握度的随机对照试验中确认。

指南或共识出处

  • 临床试验注册号:ChiCTR2300078565,注册日期2023年12月12日,注册网址https://www.chictr.org.cn/。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the feasibility and safety of a renal vein Doppler-guided central venous pressure (CVP) tritration protocol (RVD-CVP) in patients with sepsis, and to explore preliminary kidney-related and hemodynamic signals. METHOD: This prospective, single-center, parallel-group pilot randomized controlled trial was conducted in an ICU between April and December 2023. Adults with sepsis and CVP monitoring were randomized 1:1 to RVD-CVP (renal vein Doppler assessments at 0, 6, 24, 48, and 72 h with prespecified CVP targets to maintain, lower, or defer) or usual care without renal vein Doppler guidance. The primary outcome was feasibility, defined as complete protocol delivery in the intervention group. Secondary outcomes were exploratory. RESULTS: Of 173 screened patients, 127 were randomized (63 intervention; 64 control). Complete protocol delivery was achieved in 63/63 intervention patients (100.0%; 95% CI, 94.3–100.0), and all scheduled renal vein Doppler assessments were completed (315/315, 100.0%). Safety-override deferrals occurred in 17/315 assessments (5.4%). AKI progression within 7 days occurred in 37/64 control vs. 27/63 intervention patients (57.0% vs. 43.0%; RR 0.74, 95% CI 0.52–1.06). The intervention group also had a lower rate of renal replacement therapy (RRT) initiation and a shorter duration of RRT compared to the control group (9.52% vs. 23.44%, RR 0.41, 95% CI 0.17–0.98, P = 0.035; 0.84 days vs. 2.39 days, P = 0.03). 28-day mortality was 7.9% vs. 12.5%. Additionally, vasopressor-free days at day 28 were higher (mean 22.12 vs. 18.84 days) and maximum norepinephrine dose was lower (mean 0.423 vs. 0.560 µg/kg/min) in the intervention group CONCLUSION: In this pilot randomized controlled trial, renal vein Doppler ultrasound–guided CVP titration was feasible and was associated with greater de-escalation and a lower fluid balance. Differences in AKI-related outcomes and renal replacement therapy use (including CRRT) were prespecified as exploratory secondary findings, and the trial was not powered to draw definitive conclusions on clinical outcomes. These signals should be interpreted cautiously and require confirmation in a larger, adequately powered randomized controlled trial. Clinical registration number: Register URL link: https://www.chictr.org.cn/ : Date:2023-12-12: Number: ChiCTR2300078565.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Huo Y, Liu MZ, Zhu RY, et al. Impact of renal vein doppler ultrasound-guided CVP titration in sepsis: a pilot randomized controlled trial. Crit Care. 2026. PMID: 41580843. doi:10.1186/s13054-026-05842-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。